Efficacy of levonorgestrel when administered as an irradiated, slow-release injectable matrix for feline contraception

Zoo Biology

Volumn 20, Issue 5, 2001, Pages 407-421

  Looper, Sheri ^a   Anderson, Gary ^a   Sun, Yichun ^b   Shukla, Atul ^b   Lasley, Bill ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cat; Estrogen; Pregnancy; Progesterone

Indexed keywords

EID: 0035732355     PISSN: 07333188     EISSN: None     Source Type: Journal    
DOI: 10.1002/zoo.1039     Document Type: Article

References (27)

1. Baldwin CJ, Peter AT, Bosu WTK, Dubielzig RR. 1994. The contraceptive effects of levonorgestrel in the domestic cat. Lab Anim Sci 44:261-9.
2. Bauman JE, Hardin A. 1998. Measurement of steroids in animal feces with commercially available RIA kits intended for use in human serum [Abstract]. J Clin Ligand Assay 21:83.
3. Bettinger T, Cougar D, Lee RD, Lasley BL, Wallis J. 1997. Ovarian hormone concentrations and genital swelling patterns in female chimpanzees with Norplant implants. Zoo Biol 16:209-23.
4. Brache V, Faundes A, Johansson E, Alaverez F. 1985. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant® implants. Contraception 31:261-73.
5. Brache V, Alvarez F, Faundes A, Tejada AS, Cochon L. 1990. Ovarian endocrine function through five years of continuous treatment with Norplant® subdermal contraceptive implants. Contraception 41:169-77.
6. Brache V, Blumenthal PD, Alvarez F, Dunson TR, Cochon L, Faundes A. 1999. Timing of onset of contraceptive effectiveness in Norplant® implant users II. Effect on the ovarian function in the first cycle of use. Contraception 59:245-51.
7. Chen JC, Bellenger CR. 1987. Obese appearance, mammary development and retardation of hair growth following megestrol acetate administration in cats. J Sm Anim Pract 28:1161-7.
8. Concannon PW, Meyers-Wallan VN. 1991. Current and proposed methods for contraception and termination of pregnancy in dogs and cats. J Am Vet Med Assoc 198:1214-25.
9. Croxatto HB, Diaz S, Pavez M, Miranda P, Brandeis A. 1982. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants. Acta Endocr 101:307-11.
10. Faundes A, Brache V, Tejada AS, Cochon L, Sanchez FA. 1991. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Fertil Steril 56:27-31.
11. Harrenstien LA, Munson L, Seal US, The American Zoo and Aquarium Association Mammary Cancer Study Group. 1996. Mammary cancer in captive wild felids and risk factors for its development: a retrospective study of the clinical behavior of 31 cases. J Zoo Wildl Med 27:468-76.
12. Kazensky CA, Munson L, Seal US. 1998. The effects of melengestrol acetate on the ovaries of captive wild felids. J Zoo Wildl Med 29:1-5.
13. Kuhnz W, Fritzemeier C, Hegele-Hartung C, Krattenmacher R. 1995. Comparative progestational activity of norgestimate, levonorgestreloxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor. Contraception 51:131-9.
14. Lemus AE, Vilchis F, Damsky R, Chavez BA, Garcia GA, Grillasca I, Palacios GP. 1992. Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs. J Steroid Biochem Molec Biol 41:881-90.
15. Liu CQ, Shen SR, Dai MZ, Zhu JY, Liu GM, Li LZ. 1988. A comparative study on the antifertility action of levonorgestrel oxime and levonorgestrel. Yaoxue Xuebao 23:252-7.
16. Munro CJ, Laughlin LS, VonSchalscha T, Baldwin DM, Lasley BL. 1996. An enzyme immunoassay for serum and urinary levonorgestrel in human and non-human primates. Contraception 54:43-53.
17. Munson L, Bauman JE, Asa CS, Jochle W, Trigg TE. 2001. Efficacy of the GnRH-analogue des-lorelin for suppression of the oestrous cycle in cats. J Reprod Fertil Suppl 57:255-61.
18. Ratsula K, Toivonen J, Lahteenmaki P, Luukkainen T. 1989. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device. Contraception 39:195-204.
19. Savage A, Zirofsky DS, Shideler SE, Lasley BL. 1998. The use of Norplant as an effective means of contraception in the white-faced saki. Am J Primatol 45:205-11.
20. Shaaban MM, El-Nashar IM, Ghaneimah SA, Gomaa AA, Salah M, Abdel-Aleem AM. 1984. Hormonal changes during the first year of use of subdermal levonorgestrel implants, Norplant®. Contraception 30:391-405.
21. Shaaban MM, Segal S, Salem HT, Ghaneimah SA, Khalifa EA, Ahmed AG. 1993. Sonographic assessment of ovarian and endometrial changes during long-term Norplant® use and their correlation with hormonal levels. Fertil Steril 59:998-1002.
22. Shideler SE, Savage A, Ortuno AM, Moorman EA, Lasley BL. 1993. Monitoring female reproductive function by measurement of fecal estrogen and progesterone metabolites in the white-faced Saki (Pithecia pithecia). Am J Primatol 32:95-101.
23. Shirley B, Bundren JC. 1995. Effects of levonorgestrel on capacity of mouse oocytes for fertilization and development. Contraception 52:209-14.
24. Sivin, I, Viegas O, Campodonico I, Diaz S, Pavez M, Wan L, Koetsawang S, Kiriwat O, Anant MP, Holma P, Abdalla KD, Stern J. 1997. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three year study with Norplant® implants as controls. Contraception 55:73-80.
25. Tell L, Shukla A, Munson L, Thosar S, Kass P, Stanton R, Needham M, Lasley BL. 1999. A comparison of the effects of slow release, injectable levonorgestrel and depot medroxyprogesterone acetate on egg production in Japanese quail (Cotumix cotumix japonica). J Avian Med Surg 13:23-31.
26. Telleria CM, Carrizo DO, Deis RP. 1994. Levonorgestrel inhibits luteinizing hormone-stimulated progesterone production in rat luteal cells. J Steroid Biochem Mol Biol 50:161-6.
27. Wise DL, Rosenkrantz H, Gregory JB, Esber HJ. 1980. Long-term controlled delivery of levonorgestrel in rats by means of small biodegradable cylinders. J Pharmacol 32:399-403.